Skip to main content
All lobbying filings

GSK (FKA GLAXOSMITHKLINE INC.)

Lobbying for GSK (FKA GLAXOSMITHKLINE INC.)

 Filing 1st Quarter - Amendment
1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $800,000.00 expenses · posted May 6, 2025

Official filing document

 Bills named in this filing 33
  • HCONRES 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
  • SCONRES 7
    An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal ye…
  • HR 1968
    Full-Year Continuing Appropriations and Extensions Act, 2025
  • HR 9026
    To designate the facility of the United States Postal Service located at 80 Atlantic Avenue in Oceanside, New York, as …
  • HR 9027
    Military and Veterans Fuel Discount Act of 2026
  • HR 9029
    Coal Cleanup Taxpayer Protection Act of 2026
  • S 4690
    A bill to amend the Securities Act of 1933 to expand the ability to use testing the waters and confidential draft regis…
  • HR 830
    SAFE Act
  • HR 7024
    Hemp Planting Predictability Act
  • S 864
    HELP Copays Act
  • HR 950
    Saving Seniors Money on Prescriptions Act
  • S 43
    Skinny Labels, Big Savings Act
  • S 708
    RESTORE Patent Rights Act of 2025
  • S 1040
    Drug Competition Enhancement Act
  • S 1041
    Affordable Prescriptions for Patients Act
  • S 1095
    Stop STALLING Act
  • S 1096
    Preserve Access to Affordable Generics and Biosimilars Act
  • S 1097
    Interagency Patent Coordination and Improvement Act of 2025
  • HR 890
    Stopping Pharma’s Ripoffs and Drug Savings For All Act
  • HR 1574
    RESTORE Patent Rights Act of 2025
  • S 705
    Innovation in Pediatric Drugs Act of 2025
  • S 832
    EPIC Act of 2025
  • S 891
    Bipartisan Health Care Act
  • S 932
    Give Kids a Chance Act of 2025
  • HR 946
    ORPHAN Cures Act
  • HR 1262
    Mikaela Naylon Give Kids a Chance Act
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • HR 2214
    DRUG Act
  • S 4942
    Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
  • HR 198
    SERVE Our Communities Act
  • S 2973
    SHUTDOWN Act
  • S 882
    Patients Before Middlemen Act
  • S 4795
    Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025
 Lobbying activity 5
Budget/Appropriations

H.Con.Res.14: Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 S.Con.Res.7 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 H.R. 1968: Full-Year Continuing Appropriations and Extensions Act, 2025 (became Public Law No: 119-4) H.R. 9026: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025 H.R. 9027: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025 H.R. 9029: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 4690: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025 S. 4795: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025 S. 4942: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R.7024 - Tax Relief for American Families and Workers Act of 2024 S. 864, HELP Copays Act - A bill to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes. Drug cost and pricing policy issues

Medicare/Medicaid

H.R. 950: Saving Seniors Money on Prescriptions Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Insulin policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Medicaid waiver policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues

Copyright/Patent/Trademark

S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 1574: RESTORE Patent Rights Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent use codes policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues

Health Issues

S. 705: Innovation in Pediatric Drugs Act of 2025 S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 H.R. 946: Orphan Cures Act H.R. 1262: Give Kids a Chance Act of 2025 H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R. 2214: DRUG Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues Clinical trial policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Pandemic preparedness policy issues Artificial intelligence policy issues Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Provisions related to the pharmaceutical industry. Drug cost and pricing policy issues Drug importation policy issues Accelerated approval policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program Issues related to the 340B Program. Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Patent use codes policy issue Pharmacy Benefit Manager reform and policy issues Rebate policy issues S. 2973: Modernizing and Ensuring PBM Accountability Act (MEPA) S. 882, Patients Before Middlemen Act, and other legislation related to pharmacy benefit manager (PBM) reform. The Orphans Cures Act" User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Vaccine provisions of the Inflation Reduction Act

Trade (domestic/foreign)

Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem